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Abstract
Introduction—Prostate cancer is the most common cancer and the second leading cause of 
cancer death among men in the United States. African American (AA) men have greater prostate 
cancer burden than other men. Little is known about AA primary care physicians’ (PCPs) 
practices regarding prostate cancer screening.
Methods—We analyzed data from the 2007–2008 National Survey of Primary Care Physicians’ 
Practices Regarding Prostate Cancer Screening. The current study included 604 AA PCPs. 
Outcomes assessed were (a) offering screening using the prostate-specific antigen (PSA) test, (b) 
use of screening discussions to involve patients in the decision to screen, and (c) having a 
discussion policy to try to talk the patient into getting the screening tests.
Results—Most AA PCPs were male (52%), younger than 50 years (61%), and had 21% to 100% 
AA patients in their practices (74%). The majority (94%) of AA PCPs offered prostate cancer 
screening using PSA, discussed the tests with their male patients to involve them in the decision to 
screen (83%), and had a policy to try to talk the patient into getting the screening tests (77%). 
Multivariate analysis showed that offering screening, use of discussions, and a usual policy to 
encourage taking the screening tests varied mainly by practice-related factors, including practice 
type, practice location, and percentage of AA patients in the practice.
Conclusion—Data from this study indicate that most AA PCPs reported high proscreening 
behaviors for all 3 outcomes. Additionally, practice- and screening-related factors may be 
important when examining AA PCP screening behaviors.
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Prostate cancer affects nearly 200 000 men and claims about 30 000 lives each year making 
it the second leading cause of cancer death in US men.1,2 In addition to older age and family 
history, African American (AA) race is a strong risk factor for being diagnosed with prostate 
cancer. In 2009, prostate cancer incidence was about 72% greater in AA compared with 
white men and much greater than that observed among Asian, Hispanic, and men of other 
race,1 while mortality from prostate cancer was nearly 2.5 times as high among AA men 
compared with white men and even higher compared with other men.3
The clinical and scientific community lack agreement on whether to offer routine screening 
for prostate cancer to asymptomatic men, yet most primary care physicians (PCPs) offer 
screening to their male patients older than 50 years.4,5 Prostate cancer screening has been 
associated with early detection of the disease,6 and use of the digital rectal examination 
(DRE) combined with the prostate-specific antigen (PSA) as primary screening tests has 
increased over the past several years.6–8 However, the net benefits and risks of prostate 
cancer screening remain uncertain. Disagreements among the major public health 
organizations regarding routine screening continue, even for AA men who suffer a 
disproportionate burden from this disease.1
At the time this study was conducted, some organizations recommended that men should 
begin screening at age 50, and perhaps earlier if they were AA or had a known family 
history of prostate cancer.9,10 Other groups, including the US Preventive Services Task 
Force (USPSTF), differed in their recommendations.11 In 2008, the USPSTF concluded that 
current evidence was insufficient to recommend routine population-based screening with 
DRE or PSA in men younger than 75 years.12 The USPSTF also recommended against 
routine screening for prostate cancer in men 75 years or older. The most recent USPSTF 
guidelines recommend against all routine screening for prostate cancer (grade D 
recommendation).13 Currently, many organizations recommend physician–patient 
discussions about the appropriateness of screening and suggest that PCPs and patients 
engage in some form of shared decision making (SDM).11,15
Studies of PCPs and prostate cancer screening have focused on several topics, including (a) 
likelihood that US PCPs discuss and recommend prostate cancer screening with their 
patients16; (b) specific factors that influence the SDM process17; (c) the effect of general 
practitioners’ gender and age on systematic recommendation for cancer (including prostate 
cancer) screening18; (d) the extent of informed decision making for prostate cancer 
screening in a defined population19; (e) PCP demographics, knowledge of, and attitudinal 
influence toward PSA screening practices20,21; (f) use of prescreening discussions to 
promote informed decision making22; (g) guidelines that recommend SDM on physician 
practice patterns23; and (h) whether PCPs routinely discuss prostate cancer screening and the 
barriers to and facilitators of these discussions.24 Most of the above studies16–22,24 lacked 
significant numbers to examine AA PCPs as a group or AA PCP practices were not 
mentioned in the findings. Thus, it remains to be seen whether PCP prostate cancer 
screening practices described in previous literature reflect the practices of AA PCPs.
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Primary care physicians are likely the first to encounter men to discuss and offer the PSA 
test and the DRE. Two qualitative studies of PCPs in the United States sought to examine 
their screening patterns. The first study identified 2 types of physician screening behaviors: 
(a) “routine screeners” who attributed their screening practices to experience and belief in 
the benefit of PSA screening and (b) “nonroutine screeners” who cited lack of scientific 
evidence documenting the benefit of PSA screening.4 Regardless of screening pattern, both 
groups tended to recommend prostate cancer screening to most men. In a second study of 
AA PCPs, almost all reported offering the PSA test to asymptomatic non-AA men starting at 
50 years of age and to asymptomatic AA men 5 to 10 years younger.25 Most of the AA 
PCPs were proactive about screening, reporting that concerns about the seriousness of 
prostate cancer outweighed the potential limitations of screening including the risks of side 
effects from treatment.25 Both studies recommended that quantitative research should be 
conducted to explore physician characteristics in general, and AA PCP practices in 
particular, as they relate to prostate cancer screening, including individual and practice-
related characteristics4,25
The purpose of this study was to characterize prostate screening behaviors in a nationally 
representative sample of AA PCPs, a group that has been understudied in the literature, by 
individual physician-level and practice-related factors. We report PCP attitudes and 
behaviors regarding recommending prostate cancer screening to asymptomatic males during 
routine health maintenance examinations (HMEs).
Methods
In 2008, the Centers for Disease Control and Prevention completed the Survey of Primary 
Care Physicians’ Practices Regarding Prostate Cancer Screening. The questionnaire 
measured PCP attitudes, beliefs, and behaviors related to prostate cancer and prostate cancer 
screening. Information about this survey has been described elsewhere.16 The instrument 
was mailed in 2007–2008 to a nationally representative sample of PCPs with specialties in 
family and general practice as well as general internal medicine using a disproportionate 
stratified sampling design. The survey was completed by 1256 PCPs. After adjusting survey 
response for surveys that were undeliverable or returned as ineligible or deceased, the 
overall participation rate was 57% (1256/2219). This study focused on a subset of this 
sample, AA PCPs (N = 604) who were oversampled to provide reliable estimates for this 
group.
Measurement of Variables
Outcomes examined assessed the following general prostate cancer screening practices of 
AA PCPs, whether they (a) offered screening using the PSA test for asymptomatic male 
patients aged 40 years or older as part of their HME (0 = no, 1 = yes), (b) conducted 
prescreening discussions to involve patients in the decision to screen (0 = no, 1 = yes), and 
(c) discussed PSA testing with patients (0 = try to talk the patient out of getting the test or 
remain neutral, 1 = try to talk patient into getting the test). Having a policy when discussing 
the test with patients (item c above) was asked only for those who responded “yes” to 
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conducting screening discussions to involve patients in the decision to screen (item b 
above).
Physician characteristics examined included gender, age at time of survey, and number of 
years practicing medicine. Practice characteristics included practice location, type of 
practice, weekly patient volume, as well as number of hours worked per week in direct 
patient care, and percentage of AA male patients in the practice. Percentage of AA male 
patients ranged from 0% to 100%. We used the 50th percentile (20%) as a cutpoint to divide 
the variable into 2 categories. Who made the decision to be screened was the one screening-
related factor in the analysis (see Table 1 for coding).
Statistical Analyses
Data were analyzed using Proc SURVEY procedures in SAS Version 9.2 (SAS Institute, 
Cary, NC) to account for the stratified sampling design. Final sample weights adjusting for 
disproportionate stratified sampling, differential rates of eligibility, and nonresponse among 
physician subgroups were used. Proc SURVEY used these final sample weights to generate 
population-based estimates. We examined weighted percentages of AA PCPs who routinely 
screened with PSA during HMEs. Only characteristics for which P values from χ2 tests in 
bivariate analyses were <.20 were retained in the multivariate logistic regression model. 
Odds ratios (ORs) and 95% confidence intervals (CIs) were used to assess variability in the 
estimates of percentages and χ2P values were used to make comparisons within groups. 
Means were compared using the F test. Separate multivariate logistic regression models 
were used to estimate adjusted odds of offering the PSA, discussions about the screening 
tests, and encouragement (policy to talk the patient into getting the screening tests). All tests 
were 2-sided with a significance level of .05.
Results
The study sample represented 4544 AA PCPs nationally. Physicians were primarily male 
(51%) and younger than 50 years (61%). A majority (60%) of AA PCPs had practiced 
medicine 15 years or less (Table 1). For practice-related factors, the largest portions of PCPs 
served in suburban (31%) and urban inner city (31%) locations. The largest portion of PCPs 
served in solo practices (39%). A slight majority (55%) of PCPs served fewer than 100 
patients per week and nearly half worked from 31 to 40 hours per week. Most PCPs (74%) 
served between 21% and 100% AA male patients. A slight majority (53%) participated in 
some form of shared decision making as the PCP and patient/family jointly decided whether 
the patient should be screened. The majority (94%) of AA PCPs offered prostate cancer 
screening using PSA, conducted prescreening discussions with their male patients to involve 
them in the screening decision (83%), and had a discussion policy to try to talk the patient 
into getting the screening tests (77%).
Offering the PSA test to men during HMEs varied by type of practice and percentage of AA 
male patients in the practice (Table 2). Discussions about the prostate cancer screening tests 
also varied by practice location. Practices in suburban, urban inner city, and urban non–inner 
city PCPs were more likely to conduct discussions about the screening tests than PCPs in 
rural areas. Male PCPs and PCPs in solo practices were more likely to have a discussion 
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policy to try to talk the patient into getting the prostate cancer screening tests than their 
referents. Likewise, PCPs with higher weekly patient volumes, those who worked ≥31 hours 
per week, and those who served higher percentages of AA patients in the practice were more 
likely to have a discussion policy to try to talk the patient into getting the prostate cancer 
screening tests than their referents. Having a discussion policy to try to talk the patient into 
getting the screening tests also varied by who decided whether the patient should be 
screened.
After adjustment, practice-related factors were associated with offering screening, 
conducting prescreening discussions, and having a discussion policy of trying to talk the 
patient into getting the screening tests (Table 3). AA PCPs who worked in other types of 
practices had lower odds (OR = 0.15, CI = 0.05–0.49) of offering the PSA to age-
appropriate men than those in solo practices. Also, PCPs with higher percentages of AA 
patients in the practice (21% to 100%) had higher odds (OR = 2.26, CI = 1.05–4.89) of 
offering the PSA test than those with lower percentages (0% to 20%). AA PCPs who 
worked in suburban and urban inner city locations had higher odds of having discussions 
with men about prostate cancer screening tests than PCPs located in rural areas.
African American PCPs with higher percentages of AA patients in the practice had higher 
odds (OR= 1.60, CI = 1.01–2.54) of having a discussion policy to try to talk the patient into 
getting the screening tests (compared with those with lower percentages of AA patients in 
the practice; Table 3). Last, PCPs who jointly decided with the patient and family as well as 
PCPs that allowed the screening decision to be made primarily by patient and family had 
lower odds of having a discussion policy to try to talk the patient into getting the screening 
tests (compared with the PCP deciding or mostly deciding alone).
Discussion
This study used data from a national survey that examined physician-level and practice-
related factors and their associations with offering the PSA test, having prescreening 
discussions with men about prostate cancer screening tests, and the nature of these 
discussions. This study adds specificity to an earlier qualitative study of AA PCPs25 that 
noted several interesting points: (a) the gender of AA PCPs is near parity and is distributed 
somewhat differently from the general PCP population, (b) the majority of AA PCPs served 
larger percentages of AA patients considering that AAs comprise about 13% of the general 
population, and (c) a slight majority of AA PCPs and their patients were involved in some 
form of SDM.
In extending the earlier qualitative results, our study confirmed that females represent nearly 
50% of AA PCPs compared with 30% of the national PCP population.16 A recent study 
noted that male PCPs were more likely to believe in PSA screening efficacy than female 
PCPs, and female PCPs were more likely to discuss topics in general (other than prostate 
cancer screening) with patients than their male counterparts.26 Gender distribution may 
affect the proscreening tendency of AA PCPs as a group and should be examined more 
thoroughly in assessing PCP prostate cancer screening attitudes and behaviors. We also 
confirmed that AA PCPs overwhelmingly serve a largely AA patient base. Finally, we 
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corroborated that the majority (83%) of AA PCPs engage in prescreening discussions that 
may be characterized as SDM.
This study provides the new findings that practice- and screening-related factors may be 
important predictors of PCP screening behaviors. Higher percentages of AA male patients in 
the practice was a strong correlate for both offering the PSA test as well as having a 
discussion policy to try to talk the patient into getting the screening tests. In a qualitative 
study by Stroud et al25 2006, most AA PCPs mentioned that the seriousness of prostate 
cancer outweighed both limitations of screening as well as possible side effects from 
treatment. PCPs in the current quantitative analysis may also reflect sensitivity to these same 
issues.
Type of practice appeared to be an important factor for offering tests. AA PCPs in other 
types of practices were less likely to offer the PSA test than AA PCPs in solo practices. AA 
PCPs in solo practices may have had greater independence in deciding whether to offer 
screening than those in other settings. We were not able to evaluate whether PCPs operating 
in other settings may have been impacted by an organizational policy governing behavior 
related to prostate cancer screening.
Practice location was important for having physician discussion with patients. AA PCP 
practices located in suburban and inner city areas were more likely to have discussions with 
their patients about prostate cancer screening than their rural counterparts. As most health 
organizations recommend some form of SDM, AA patients located in rural areas may be at a 
disadvantage because these PCPs were least likely to have discussions about the screening 
tests. Additional research should be conducted to provide some clarity for this finding.
Finally, when the PCP primarily decided whether the patient should take the screening tests, 
the discussion policy was mainly to try to talk the patient into getting the screening tests. 
This finding is consistent with prior literature that found most discussions emphasized the 
pros of screening more often than the cons.26 Additionally, given the high percentage of AA 
male patients in the client base of these PCPs (data not shown), AA PCPs may show more 
protective behavior because of lower health literacy among their patient base.27
Overall, AA PCPs reported high proscreening behaviors in the 3 outcomes examined: 
offering the PSA test, conducting discussions with patients about the screening tests, and 
having a discussion policy to try to talk the patient into getting the screening tests. A 
strength of this study is that it includes one of the largest, most comprehensive surveys to 
date of prostate cancer screening practices. This study oversampled AA PCPs, representing 
nearly 5000 PCPs nationally whose prostate cancer screening practices are relatively 
unknown. Our findings about AA PCP attitudes and behaviors relative to prostate cancer 
screening offer information that could not be obtained from earlier PCP qualitative 
studies.4,25 The current study explores more variables that specifically relate to prostate 
cancer screening compared with other general PCP studies.18,28
This study is limited by its use of mailed surveys and reliance on nonvalidated data derived 
from self-reports of PCPs.29–31 Also, when PCPs tried to talk the patient into getting the 
screening tests, we were not sure whether the PCP discussion policy was formal or informal. 
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Formal organizational policies may influence physicians’ flexibility in their screening 
recommendations. We also had no information on the content of the discussions, that is, if 
the discussions covered the benefits and limitations of screening, if patients had ample time 
to ask questions, and so on. Finally, this study was conducted before the newer American 
Cancer Society prostate cancer screening guidelines (2010) and the most recent USPSTF 
guidelines (2011) were released, thus results may or may not adequately reflect PCPs 
following of current screening guidelines that support some form of informed or shared 
decision making.14
Whether to offer the PSA test to AA men poses a challenge because organizations and PCPs 
are not in agreement about prostate cancer screening. The USPSTF acknowledges that AA 
men represented a small minority of participants in randomized clinical trials of screening 
and no firm conclusions can be made about the balance of benefits and risks of PSA-based 
screening in this population.32 Therefore, a discussion regarding the benefits and risks of the 
disease should be conducted that includes specific risk of prostate cancer burden to higher 
risk groups (eg, men with a family history of prostate cancer and AA men). Other challenges 
to these discussions include getting men to go to the doctor oftentimes at earlier ages, 
promoting better provider–patient communication, and obtaining updated educational 
materials including brochures, pamphlets, and anatomical models.25 This study serves to 
enlighten both researchers and clinicians about some of the practices of AA PCPs and also 
identifies specific individual- or practice-related factors associated with prostate cancer 
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Table 1
Selected Characteristics of US African American Primary Care Physicians.
All AA PCPsa
n Weighted n Percentage
PCP characteristics
All PCPs 604 4544 100.0
Individual
Gender
 Male 313 2380 51.4
 Female 291 2164 48.6
Age (years)
 32–49 359 2710 60.8
 50+ 238 1744 39.2
Years practicing medicine
 1–15 363 2710 60.3
 16+ 229 1783 39.7
Practice related
 Practice location
  Rural 93 724 16.4
  Suburban 187 1380 31.3
  Urban inner city 178 1365 30.9
  Urban non–inner city 130 943 21.4
 Type of practice
  Solo practice 221 1718 38.7
  Single specialty group 173 1265 28.5
  Multispecialty group 169 1245 28.1
  Other type of practice 27 207 4.7
 Weekly patient volume
  <100 patients per week 329 2483 55.3
  100+ patients per week 267 2004 44.7
 Hours worked per week
  0–30 132 989 23.0
  31–40 278 2076 48.4
  41+ 163 1228 28.6
 % AA in practice
  0–20 160 176 25.9
  21–100 444 3368 74.1
Screening related
 Who decides whether patient should be screened?
  PCP decides or mostly decides 196 1486 33.7
  PCP and patient/family decide 312 2349 53.3
  Patient/family decide or mostly decide 79 571 13.0
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All AA PCPsa
n Weighted n Percentage
 PCP screening practices
 Routinely offer PSA to asymptomatic males during HMEs
  No 37 275 6.2
  Yes 562 4193 93.8
 Discuss screening to involve patients in the decision about screening
  No or restricted discussion 103 779 17.4
  Yes, discussion with all patients 498 3712 82.6
 Policy when discussing PSA with patients
  Remain neutral or discourage test 141 1014 23.5
  Try to talk patient into getting the test 436 3298 76.5
Abbreviations: AA, African American; PCP, primary care physician; PSA, prostate-specific antigen; HME, health maintenance examination.
a
Unweighted frequencies, weighted numbers, and weighted percentages of column based on valid responses for category.
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